<DOC>
	<DOCNO>NCT00003542</DOCNO>
	<brief_summary>RATIONALE : Interferon alfa may interfere growth cancer cell . PURPOSE : Phase I/II trial study effectiveness interferon alfa treat patient advanced kidney cancer .</brief_summary>
	<brief_title>Interferon Alfa Treating Patients With Advanced Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose ( MTD ) pegylated-interferon alfa-2a patient advance metastatic renal cell carcinoma . II . Evaluate safety profile MTD patient population . III . Determine objective response rate , time response , duration response , time progression , survival rate patient population . OUTLINE : This dose escalation , open label , multicenter study . Patients receive pegylated-interferon alfa-2a ( PEG-IFN ) subcutaneously week 24 week . Dose escalation PEG-IFN continue maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose limit toxicity . After MTD PEG-IFN determine , additional patient treat dose level . These patient may continue treatment first 24 week 1 year , absence disease progression . Patients follow 4 week . PROJECTED ACCRUAL : A total 46-58 patient accrue study within 9 month .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm advanced metastatic renal cell carcinoma Bidimensionally measurable lesion irradiate Minimum indicator lesion size : Liver , soft tissue , mass one diameter least 20 mm ( evaluable radiographically ) Lung one diameter least 10 mm xray CT scan Skin lesion lymph node one diameter least 10 mm clinical measurement No clinical radiologic evidence CNS metastases PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 80100 % Life expectancy : Not specify Hematopoietic : WBC least 3000/mm3 Neutrophil count least 1500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 10 g/dL ( red cell transfusion allow ) Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) ( except patient Gilbert 's syndrome ) ALT and/or AST great 2.5 time ULN ( great 4 time ULN liver metastasis ) Alkaline phosphatase great 2.5 time ULN ( great 4 time ULN liver metastasis ) Renal : Creatinine great 1.5 time ULN Cardiovascular : No history severe cardiac disease : New York Heart Association class II ( due cancer ) , III , IV Myocardial infarction within past 6 month Ventricular tachyarrhythmias require ongoing treatment Unstable angina Other : Not pregnant nursing Fertile patient must use effective contraception No prior concurrent malignancy except basal cell carcinoma skin , carcinoma situ cervix , malignancy patient disease free least 2 year No history medically significant psychiatric disease , especially depression No history evidence retinopathy No seizure disorder PRIOR CONCURRENT THERAPY : Biologic therapy : No prior concurrent immunotherapy , biologic response modifier , cytokine , monoclonal antibody , antitumor vaccine , systemic therapy Chemotherapy : No prior concurrent chemotherapy Endocrine therapy : No prior concurrent hormone therapy Hormone replacement adrenalectomy allow Radiotherapy : Prior radiotherapy allow No concurrent radiotherapy Surgery : Prior nephrectomy allow Other : No concurrent investigational drug No concurrent anticonvulsant therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>stage III renal cell cancer</keyword>
	<keyword>stage IV renal cell cancer</keyword>
</DOC>